A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3497-0
Abstract: PurposeThe response rate of ifosfamide (IFM) monotherapy for small-cell lung cancer (SCLC) is reported as 42.4% in Japanese package insert. However, these efficacy data are based on clinical studies conducted in 1970s. This phase II… read more here.
Keywords: therapy recurrent; supportive therapy; heavily treated; combination recommended ... See more keywords
Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma - How far have we achieved?
Sign Up to like & getrecommendations! Published in 2017 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.03.030
Abstract: Nasopharyngeal carcinoma (NPC) is endemic in Southern China, Taiwan, Malaysia, Singapore, North Africa and Alaska. About 30% of NPC patients develop recurrence or metastasis despite initial radical treatment. Palliative chemotherapy is the first-line treatment for… read more here.
Keywords: systemic therapy; nasopharyngeal carcinoma; therapy recurrent; palliative systemic ... See more keywords
Radiation Therapy for Recurrent or Residual Pituitary Macroadenoma Invading Extrasellar Structures
Sign Up to like & getrecommendations! Published in 2022 at "Yonsei Medical Journal"
DOI: 10.3349/ymj.2022.0323
Abstract: Purpose This study aimed to evaluate the efficacy of radiation therapy (RT) for recurrent or residual pituitary macroadenoma (PMA) invading extrasellar regions. Materials and Methods Patients from 2000 to 2020 who received RT with conventional… read more here.
Keywords: pma; therapy recurrent; recurrent residual; residual pituitary ... See more keywords